Muscle relaxation medicine
By developing a new compound formula (I), the problem of surgical recovery difficulties and postoperative comorbidities caused by the residual muscle relaxation drug is solved, and the effect of rapidly disappearing muscle relaxation is achieved, reducing the risk of allergic reactions, and in emergencies, Deep muscle relaxation support is provided.
Patent Information
- Application Number
- CN202380031126.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-12
AI Technical Summary
Existing muscle relaxants remain after the operation, resulting in the inability to recover quickly, affecting the efficiency of the surgery and increasing the risk of postoperative respiratory organ comorbidities, and the use of antagonists is complex and there is a risk of allergic reactions.
Develop a new compound, general formula (I), which has a short duration of action as a muscle relaxant, can disappear quickly, and achieve muscle relaxation without antagonists, reduce the risk of allergic reactions, and provide in emergencies. Deep muscle relaxation.
The compound's action duration is shorter than succinylcholine and is easy to manage. It can maintain deep muscle relaxation effect in emergencies, reduce the adverse effects of long-term muscle relaxation, and avoid the use of antagonists and reduce the risk of allergic shock.
Smart Images

Figure CN118946548A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel compound and a medicine which uses the novel compound as an effective ingredient and has a muscle relaxant effect. Background Art
[0002] Muscle relaxants are used to facilitate tracheal intubation required during general anesthesia and to prevent body movement during surgery, but their effects are not needed after the surgery. If the muscle relaxant effect remains, it will be impossible to disengage from artificial respiration, delaying exit from the operating room, and adversely affecting efficient operating room operations. In addition, the presence of muscle relaxants also has a negative impact on the occurrence of postoperative respiratory complications. Therefore, clinically, muscle relaxants that disappear quickly and have a short duration of action are sought.
[0003] At present, the muscle relaxants used in clinical anesthesia include depolarizing muscle relaxants (succinylcholine) and non-depolarizing muscle relaxants (rocuronium). As for the non-depolarizing muscle relaxant (rocuronium), the disappearance of the effect can be promoted by administering an antagonist (sugammadex), but there is a difficulty that complex management is required. In addition, as for the antagonist (sugammadex), there are many side effects such as allergic reactions. Therefore, it can be said that succinylcholine, which can be expected to disappear quickly without administering an antagonist, is simple and easy to use.
[0004] Succinylcholine is an old drug that has been clinically used since around 1950, but a muscle relaxant that disappears faster than succinylcholine in natural recovery (without administration of antagonists) has not yet been developed. However, the duration of action at the clinically used dose is reported to be about 10 minutes (Non-patent Document 1), which is not sufficient if it is assumed that a situation such as ventilation failure and intubation requires urgent recovery from a muscle relaxation state.
[0005] Prior art literature
[0006] Non-patent literature
[0007] Non-patent literature 1: Schmartz D, Chenard L, Baumann C, Fuchs-Buder T. Amodified train-of-four ratio to assess recovery from depolarizing neuromuscular blockade after succinylcholine, a prospective observational study.J Clin MonitComput.2021Oct;35(5):1133-1138.doi:10.1007 / s10877-020-00560-5 Summary of the invention
[0008] Problems to be solved by the invention
[0009] The technical problem of the present invention is to provide a compound which can be used as a muscle relaxant with a short duration of action and a rapid disappearance of the action.
[0010] Solutions for solving problems
[0011] The present inventors have conducted intensive studies to solve the above-mentioned technical problems and have found that the compound represented by the general formula (I) exhibits excellent effects as a muscle relaxant with a short duration of action, thereby completing the present invention.
[0012] That is, one embodiment of the present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for use as a muscle relaxant comprising the compound or a pharmacologically acceptable salt thereof as an active ingredient.
[0013] Effects of the Invention
[0014] The present invention provides a compound group, characterized in that the duration of muscle relaxation is short. In more detail, the duration of action of the compound of the present invention is shorter than that of succinylcholine, which has the shortest duration of action among the muscle relaxants currently used clinically. Therefore, there is no need to consider the strict adjustment of the dosage and administration speed of the duration of action, and it is easy to manage clinically. In addition, by increasing the dosage, the expression of the effect is accelerated, and the deep muscle relaxation effect can be stably maintained by continuous administration, even in situations where ventilation and intubation are impossible and it is necessary to urgently recover from the muscle relaxation state. In addition, the disadvantages caused by the long-term persistence of the muscle relaxation effect can be avoided, and no antagonist is required to promote the disappearance of the effect, so the risk of anaphylactic shock can be reduced, and it also has the advantage of being able to be administered again during reoperation. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a graph showing a comparison of the duration of action when JH013 or succinylcholine was administered to rats at an amount that produces 95% to 99.9% neuromuscular blockade (ED95-99.9).
[0016] Figure 2 This is a graph showing a comparison of the duration of action when JH014 or succinylcholine was administered to rats at an amount that produces 95% to 99.9% neuromuscular blockade (ED95-99.9). DETAILED DESCRIPTION
[0017] The compound of the present invention is represented by the general formula (I).
[0018]
[0019] Here, X 1 , X 2 , X 3 and X 4 Each independently represents hydrogen or an alkoxy group having 1 to 3 carbon atoms, X 1 , X 2 , X 3 and X 4 At least two of them are alkoxy groups having 1 to 3 carbon atoms, preferably X 1 , X 2 , X 3 and X 4 Both of them are alkoxy groups having 1 to 3 carbon atoms, and X is more preferably 2 and X 3 is an alkoxy group having 1 to 3 carbon atoms, X 1 and X 4 The alkoxy group having 1 to 3 carbon atoms is preferably a methoxy group.
[0020] Y 1 , Y 2 , Y 3 , Y 4 and Y 5 Each independently represents hydrogen or an alkoxy group having 1 to 3 carbon atoms, and Y 1 , Y 2 , Y 3 , Y 4 and Y 5 At least two of them are alkoxy groups having 1 to 3 carbon atoms, preferably Y 1 , Y 2 , Y 3 , Y 4 and Y 5 Both of them are alkoxy groups having 1 to 3 carbon atoms. 1 , Y 2 , Y 3, Y 4 and Y 5 Y 3 is an alkoxy group having 1 to 3 carbon atoms and Y 2 and Y 4 Any one of them is an alkoxy group having 1 to 3 carbon atoms, and the rest are hydrogen. The alkoxy group having 1 to 3 carbon atoms is preferably a methoxy group.
[0021] n is 0 or 1, preferably 1.
[0022] L represents a linking group having 5 to 20 atoms in the main chain, preferably a linking group having 5 to 16 atoms in the main chain, more preferably a linking group having 7 to 16 atoms in the main chain, further preferably a linking group having 8 to 13 atoms in the main chain, even more preferably a linking group having 9 to 12 atoms in the main chain, and particularly preferably a linking group having 10 to 11 atoms in the main chain.
[0023] L is preferably one or more (preferably two or more, more preferably two to four, and even more preferably two) -CH 2 - A divalent group substituted by -O- or -O-C(=O)- or -C(=O)-O-. In the divalent group, one or more hydrogen atoms may be substituted by halogen atoms.
[0024] L is represented by, for example, the following general formulae (II) to (V).
[0025]
[0026] In the general formulas (II) to (V), -(L') n3 - is an alkylene or alkenylene group having 1 to 6 carbon atoms in which one or more hydrogen atoms are optionally replaced by halogen (e.g., Cl, F or Br), n1 is an integer of 1 to 5 (preferably 1 to 3), and n2 is an integer of 1 to 5 (preferably 1 to 3).
[0027] In another embodiment, L is represented by, for example, the following general formula (VI).
[0028]
[0029] Here, -(L") n4 - is an alkylene or alkenylene group having 1 to 6 carbon atoms in which one or more hydrogen atoms are optionally substituted by halogen, n1 is an integer of 1 to 5 (preferably 1 to 3), and n2 is an integer of 1 to 5 (preferably 1 to 3).
[0030] Examples of the compound of general formula (I) include the following compounds.
[0031]
[0032]
[0033]
[0034]
[0035] The compound of the general formula (I) can be synthesized by the method according to the Examples.
[0036] The salt of the compound of general formula (I) is not particularly limited as long as it is a pharmacologically acceptable salt, and examples thereof include acid addition salts. Examples of acid addition salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid, and salts with organic acids such as acetic acid, malic acid, succinic acid, tartaric acid, citric acid, fumaric acid, oxalic acid, and p-toluenesulfonic acid, and chlorine.
[0037] When the compound of general formula (I) has an asymmetric carbon atom in the molecule, it may exist in the form of multiple stereoisomers (i.e., diastereomers, optical isomers) based on the asymmetric carbon atom, and the present invention includes any one of the stereoisomers or a mixture thereof.
[0038] The compound of the general formula (I) may include cis- and trans-isomers as geometric isomers, and when the compound has axial asymmetry in the molecule, may include isomers based on the axial asymmetry, and includes any one of these isomers or a mixture thereof.
[0039] The compound of the present invention may be prepared as a pharmaceutical composition in which a pharmacologically acceptable carrier is mixed with the compound of the general formula (I) or a salt thereof as an active ingredient.
[0040] Here, as pharmacologically acceptable carriers, there can be listed: commonly used excipients, binders, disintegrants, lubricants, and various carriers, stabilizers, surfactants, plasticizers, lubricants, solubilizers, reducing agents, buffers, sweeteners, bases, adsorbents, flavoring agents, suspending agents, antioxidants, glossing agents, coatings, coatings, wetting agents, moisture regulators, fillers, defoamers, cooling agents, colorants, flavoring agents, fragrances, sugar coating agents, isotonic agents, softeners, emulsifiers, thickeners, thickeners, foaming agents, pH adjusters, diluents, dispersants, disintegration aids, disintegration delay agents, fragrances, anti-humidification agents, preservatives, solubilizers, dissolution aids, solvents, fluidizing agents, antistatic agents, bulking agents, humectants, humectants, humectants, and the like.
[0041] The dosage form of the medicine is not particularly limited, and examples thereof include liquid, injection, inhalant, external preparation, tablet, capsule, emulsion, etc. The administration route is not particularly limited, and the medicine can be formulated as a parenteral preparation for subcutaneous, intramuscular, rectal, or intranasal administration.
[0042] The amount of the compound of general formula (I) or a salt thereof as an active ingredient in the pharmaceutical composition is not particularly limited as long as it is an amount effective for expressing the effect as a medicine. It usually varies depending on the dosage form, but the amount of the active ingredient can be set in a manner that can achieve the desired dosage, for example, within the range of about 0.01 mass % to about 99.9 mass %.
[0043] The medicine comprising the compound of the general formula (I) of the present invention or a salt thereof can be preferably used as a muscle relaxant.
[0044] Muscle relaxants are classified into central muscle relaxants and peripheral muscle relaxants according to their site of action. They can be used clinically for example to treat spastic paralysis, improve muscle tension, relax muscles during anesthesia or endotracheal intubation, malignant syndrome (Dantrolene), blepharospasm (botulinum toxin), etc.
[0045] The ideal dosage of the compound of formula (I) or a salt thereof varies depending on the subject, dosage form, administration method, administration period, etc., and in order to obtain the desired effect, 0.5 to 1000 mg, preferably 1 to 500 mg, can be administered to an adult.
[0046] As other aspects of the present invention, for example, the following can be cited.
[0047] A method for muscle relaxation, comprising: administering a compound of general formula (I) or a salt thereof to a subject in need of the compound of general formula (I) or a salt thereof.
[0048] A method for treating spastic paralysis, comprising administering a compound of general formula (I) or a salt thereof to a subject in need of the compound of general formula (I) or a salt thereof.
[0049] A method for improving muscle tension, comprising: administering a compound of general formula (I) or a salt thereof to a subject in need of the compound of general formula (I) or a salt thereof.
[0050] A method for treating malignant syndrome, comprising: administering a compound of general formula (I) or a salt thereof to a subject in need of the compound of general formula (I) or a salt thereof.
[0051] A method for treating blepharospasm, comprising administering a compound of general formula (I) or a salt thereof to a subject in need of the compound of general formula (I) or a salt thereof.
[0052] Furthermore, as other aspects of the present invention, for example, the following can be cited.
[0053] A compound of general formula (I) or a salt thereof for use as a muscle relaxant.
[0054] A compound of general formula (I) or a salt thereof for use in the treatment of spastic paralysis.
[0055] A compound of general formula (I) or a salt thereof for use in improving muscle tension.
[0056] A compound of general formula (I) or a salt thereof for use in the treatment of malignant syndrome.
[0057] A compound of general formula (I) or a salt thereof for use in the treatment of blepharospasm.
[0058] Furthermore, as other aspects of the present invention, for example, the following can be cited.
[0059] Use of a compound of general formula (I) or a salt thereof in the production of a muscle relaxant.
[0060] Use of a compound of general formula (I) or a salt thereof in the manufacture of a medicament for treating spastic paralysis.
[0061] Use of a compound of general formula (I) or a salt thereof in the manufacture of a medicament for improving muscle tension.
[0062] Use of a compound of general formula (I) or a salt thereof in the manufacture of a medicament for treating malignant syndrome.
[0063] Use of a compound of general formula (I) or a salt thereof in the manufacture of a medicament for treating blepharospasm.
[0064] Example
[0065] Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to the embodiments below.
[0066] Synthesis scheme of compound JH013
[0067]
[0068] <Synthesis of Intermediate 1>
[0069] 3-Chloro-1-propanol (3.32 mL, 40.0 mmol) was added to (±)-laudanosine (2.86 g, 8.00 mmol) and heated at 105°C for 14 hours. After cooling, acetonitrile (5 mL) was added to completely dissolve the precipitated target substance, and the reaction solution was added dropwise to diisopropyl ether (150 mL), and the precipitated solid was filtered out. The same operation was repeated twice for the obtained solid, and the obtained crude product (3.71 g) was purified by medium pressure silica gel column chromatography (diol-based silica gel 100 g, dichloromethane / methanol = 100 / 0 to 95 / 5) to obtain Intermediate 1 (1.46 g, 3.23 mmol, yield 40%) as a pale yellow solid with a diastereoisomer mixture of about 3:2. The recovered low-purity intermediate 1 (1.66 g) was purified by medium-pressure silica gel column chromatography (arginine silica gel 10 g, acetonitrile / water = 100 / 0 to 97 / 3) to obtain intermediate 1 (0.905 g, 2.00 mmol, yield 25%). The recovered low-purity intermediate 1 (0.519 g) was further purified by medium-pressure silica gel column chromatography (arginine silica gel 10 g, acetonitrile / water = 100 / 0 to 97 / 3) to obtain intermediate 1 (0.221 g, 0.489 mmol, yield 6%). (1H NMR, LCMS: Chart 1-3)
[0070] 1H NMR (270MHz, DMSO-d6): δ6.90-6.75 (m, 2H), 6.71 (s, 0.6H), 6.60-6.45 (m, 1.4H), 5.71 (s, 0.4H), 5.65 (s, 0.6H), 4.99 ( t, 0.4H, J=4.9Hz), 4.82-4.60 (m, 1.6H), 3.90-3.48 (m, 14H), 3.48-3.18 (m, 7H), 3.18-2.75 (m, 4H), 2.17-1.86 (m, 2H).
[0071] LCMS (ESI+): m / z calcd for [M]+ = 417.1, RT: 1.05 min.
[0072] <Synthesis of JH013>
[0073] Fumaryl chloride (0.673 mL, 6.20 mmol) was dissolved in dichloromethane (10 mL), and dried MS4A (1.40 g) was added, and the mixture was cooled to 0°C in an ice bath. A solution of intermediate 1 (1.40 g, 3.10 mmol) in dichloromethane (18 mL) was added dropwise to the solution over 20 minutes, and the mixture was stirred at room temperature for 2 hours. Choline chloride (1.70 g, 12.2 mmol) was added, and the mixture was further stirred at room temperature for 20 hours. The target substance precipitated as a viscous solid was filtered out, and the obtained solid was dissolved in a mixed solution of acetonitrile / methanol = 95 / 5 (50 mL), and MS4A was filtered out. The filtrate was carefully concentrated at room temperature, and the obtained crude product (3.33 g) was purified by medium pressure silica gel column chromatography (arginine silica gel 60 g, acetonitrile / water = 100 / 0 to 90 / 10). The eluate was lyophilized while maintaining the state, thereby obtaining JH013 (2.02 g) containing choline chloride and the like as a colorless solid. The JH013 was further purified by medium-pressure silica gel column chromatography (ODS silica gel 60 g, acetonitrile / water = 1 / 99 to 5 / 95), and the eluate was lyophilized while maintaining the state, thereby obtaining JH013 (727 mg, 1.08 mmol, yield 35%) as a colorless solid diastereoisomer mixture of about 7:3. (1H NMR, LCMS: Chart 4-6)
[0074] 1H NMR (270MHz, DMSO-d6): δ6.90-6.80 (m, 2.7H), 6.76-6.69 (m, 2H), 6.61-6.5 1(m, 1.3H), 5.70(s, 0.3H), 5.63(s, 0.7H), 4.88-4.78(m, 0.3H), 4.78-4.67 (m, 0.7H), 4.64-4.52 (m, 2H), 4.40-4.31 (m, 0.6H), 4.25-4.06 (m, 1.4H), 3. 93-3.50 (m, 14H), 3.50-3.01 (m, 19H), 2.95-2.82 (m, 1H), 2.43-2.15 (m, 2H).
[0075] LCMS (ESI+): m / z calcd for [M]2+=300.7, RT: 1.02, 1.07 min.
[0076] Synthesis scheme of compound JH014
[0077]
[0078] <Synthesis of Intermediate 2>
[0079] Chloroethanol (7.72 mL, 115 mmol) was added to (±)-laudanine (8.22 g, 23.0 mmol) and heated at 110°C for 14 hours. After cooling, acetonitrile (15 mL) was added to completely dissolve the precipitated target substance, and the reaction solution was added dropwise to diisopropyl ether (300 mL), and the precipitated solid was filtered out. The same operation was repeated twice on the obtained solid, and the obtained crude product (11.6 g) was purified by medium pressure silica gel column chromatography (diol-based silica gel 100 g, dichloromethane / methanol = 100 / 0 to 95 / 5) to obtain intermediate 2 (8.52 g) as a mixture. The mixture was divided into two parts, each of which was purified by medium pressure silica gel column chromatography (arginine silica gel 60g, acetonitrile / water = 97 / 3), thereby obtaining intermediate 2 (6.33g, 14.5mmol, yield 63%) in the form of a diastereoisomer mixture of about 7:3 as a pale yellow solid. Here, the recovered low-purity intermediate 2 (1.29g) was further purified by medium pressure silica gel column chromatography (arginine silica gel 30g, acetonitrile / water = 100 / 0 to 97 / 3) to obtain intermediate 2 (0.780g, 1.78mmol, yield 8%). (1H NMR, LCMS: Chart 7-9)
[0080] 1H NMR (270MHz, DMSO-d6): δ6.90-6.78 (m, 2H), 6.70 (s, 0.7H), 6.65 (s, 0.3H), 6.58-6.5 1(m, 0.7H), 6.51-6.44(m, 0.3H), 6.58-6.44(m, 1H), 5.71(t, 0.3H, J=4.9Hz), 5.64(s , 1H), 5.48(t, 0.7H, J=4.9Hz), 4.95-4.77(m, 1H), 4.15-4.00(m, 0.6H), 3.95-3.54(m , 13.4H), 3.43-3.27(m, 4H), 3.27-3.20(m, 3H), 3.17-3.03(m, 3H), 2.92-2.72(m, 1H).
[0081] LCMS (ESI+): m / z calcd for [M]+ = 403.1, RT: 0.93 min.
[0082] <Synthesis of JH014>
[0083] Fumaryl chloride (0.897 mL, 8.27 mmol) was dissolved in dichloromethane (22.5 mL), and dried MS4A (1.81 g) was added, and the mixture was cooled to 0°C in an ice bath. A solution of intermediate 2 (1.81 g, 4.13 mmol) in dichloromethane (10 mL) was added dropwise to the solution over 10 minutes, and the mixture was stirred at room temperature for 5 hours. Choline chloride (2.31 g, 16.5 mmol) was added, and the mixture was further stirred at room temperature for 61 hours. The target substance precipitated as a viscous solid was filtered out, and the obtained solid was dissolved in a mixed solution of acetonitrile / methanol = 95 / 5 (100 mL), and MS4A was filtered out. The filtrate was carefully concentrated near room temperature, and the obtained crude product (3.87 g) was purified by medium pressure silica gel column chromatography (arginine silica gel 90 g, acetonitrile / water = 100 / 0 to 93 / 7). The eluate was lyophilized while maintaining the state, thereby obtaining JH014 (927 mg) containing choline chloride and the like as a colorless solid. The JH014 was further purified by medium-pressure silica gel column chromatography (ODS silica gel 60 g, acetonitrile / water = 1 / 99 to 5 / 95), and the eluate was lyophilized while maintaining the state, thereby obtaining JH014 (586 mg, 0.891 mmol, yield 22%) as a colorless solid diastereoisomer mixture of about 3:1. (1H NMR, LCMS: Chart 10-12)
[0084] 1H NMR (270MHz, DMSO-d6): δ6.94-6.74 (m, 4.75H), 6.65 (s, 0.25H), 6.57-6.50 (m, 1H), 5.71 (s, 0.25H), 5.57 (s, 0.75H), 5.05 -4.97(m, 0.25H), 4.88-4.78(m, 1.25H), 4.72-4.55(m, 3.5H), 4.00-3.55(m, 14H), 3.50-3.05(m, 19H), 2.93-2.80(m, 1H).
[0085] LCMS (ESI+): m / z calcd for [M]2+=293.7, RT: 1.00, 1.05 min.
[0086] <Evaluation of muscle relaxation effect>
[0087] Male Sprague Dawley rats (weighing about 300 g) were used in the experiment. First, anesthesia was induced by inhalation of 4-5% isoflurane, and then anesthesia was maintained by inhalation of 2-3% isoflurane. A warming device was used to maintain the body temperature at 36-37°C. Lidocaine was infiltrated into the incision site. A tracheotomy was performed, and a 16G catheter was inserted to secure the airway. A rodent ventilator was used to inhale isoflurane and oxygen, with a ventilation volume of 10 mL / kg and a respiratory rate of 70 times / minute. A 24G catheter was placed in the right jugular vein for drug administration. A micro-sliding electrode was attached to the sciatic nerve, and supramaximal stimulation was performed with a frequency of 0.1 Hz and a pulse width of 0.2 ms using an electrical stimulation device. A single contraction response of the gastrocnemius muscle was captured using a force sensor and amplified and recorded. After the size of the single contraction reaction stabilized, succinylcholine or JH-cpd series (JH013, JH014) was administered in an amount that produced 95% to 99.9% neuromuscular blockade, and the time until muscle contraction (single contraction reaction) completely recovered was measured.
[0088] As a result, when succinylcholine was administered, the time until muscle contraction (single contraction reaction) was completely recovered was 11 minutes, while that for JH013 was 5.5 minutes ( Figure 1 ), JH014 is 7.5 minutes ( Figure 2 ). That is, it can be said that JH013 can shorten the duration of action to about 1 / 2 of the duration of action of succinylcholine, and JH014 can shorten the duration of action to about 2 / 3 of the duration of action of succinylcholine.
Claims
1. A compound or a pharmacologically acceptable salt thereof, wherein the compound is represented by the general formula (I): In the general formula (I), X1, X2, X3 and X4 each independently represent hydrogen or an alkoxy group having 1 to 3 carbon atoms, and at least two of X1, X2, X3 and X4 are alkoxy groups having 1 to 3 carbon atoms, Y1, Y2, Y3, Y4 and Y5 each independently represent hydrogen or an alkoxy group having 1 to 3 carbon atoms, and at least two of Y1, Y2, Y3, Y4 and Y5 are alkoxy groups having 1 to 3 carbon atoms, n is 0 or 1, L represents a linking group having 5 to 20 atoms in the main chain.
2. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein X1 and X4 are hydrogen, X2 and X3 are alkoxy groups having 1 to 3 carbon atoms, and Y3 among Y1, Y2, Y3, Y4 and Y5 is an alkoxy group having 1 to 3 carbon atoms, and any one of Y2 and Y4 is an alkoxy group having 1 to 3 carbon atoms, and the rest are hydrogen.
3. The compound according to claim 1 or 2 or a pharmacologically acceptable salt thereof, wherein: L is a divalent group in which one or more -CH2- groups are replaced by -O-, -O-C(=O)-, or -C(=O)-O-, and one or more hydrogen atoms are optionally replaced by halogen in an alkylene or alkenylene group having 5 to 20 carbon atoms in the main chain.
4. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 3, wherein L is represented by any of the following general formulas (II) to (V), Here, -(L') n3 - is an alkylene or alkenylene group having 1 to 6 carbon atoms in which one or more hydrogen atoms are optionally substituted by halogen, n1 is an integer of 1 to 5, and n2 is an integer of 1 to 5.
5. The compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 3, wherein L is represented by the following general formula (VI), Here, -(L") n4 - is an alkylene or alkenylene group having 1 to 6 carbon atoms in which one or more hydrogen atoms are optionally substituted by halogen, n1 is an integer of 1 to 5, and n2 is an integer of 1 to 5.
6. The compound according to claim 4 or a pharmacologically acceptable salt thereof, wherein The compound represented by general formula (I) is any of the following compounds, 7 . A pharmaceutical composition comprising: the compound according to claim 1 or a pharmacologically acceptable salt thereof; and a pharmacologically acceptable carrier.
8. The pharmaceutical composition according to claim 7, wherein The pharmaceutical composition is used as a muscle relaxant.
